scholarly journals Tumor-suppressive effect of connexin 32 in renal cell carcinoma from maintenance hemodialysis patients

2003 ◽  
Vol 63 (1) ◽  
pp. 381 ◽  
Author(s):  
Tomohiro Yano ◽  
Fumio Ito ◽  
Haruna Satoh ◽  
Kiyokau Hagiwara ◽  
Hayakazu Nakazawa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Suppressive Effect ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Connexin 32 ◽  
Tumor Suppressive Effect ◽  
Maintenance Hemodialysis Patients

scholarly journals Epigenetic inactivation of connexin 32 in renal cell carcinoma from hemodialytic patients

2004 ◽  
Vol 65 (4) ◽  
pp. 1519 ◽  
Author(s):  
Tomohiro Yano ◽  
Fumio Ito ◽  
Hiroshi Yamasaki ◽  
Kiyokazu Hagiwara ◽  
Hisashi Ozasa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Connexin 32 ◽  
Epigenetic Inactivation

scholarly journals Three cases of spindle cell renal cell carcinoma in hemodialysis patients

2015 ◽  
Vol 48 (10) ◽  
pp. 599-604
Author(s):  
Kazuma Tsujimura ◽  
Hiroki Shirakawa ◽  
Junpei Hasegawa ◽  
Mariko Endou ◽  
Sachiko Wakai ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Spindle Cell ◽  
Hemodialysis Patients ◽  
Cell Renal Cell Carcinoma

Acquired Renal Cystic Disease and Its Complications in Continuous Ambulatory Peritoneal Dialysis Patients

1992 ◽  
Vol 12 (3) ◽  
pp. 292-297 ◽  
Author(s):  
Isao Ishikawa
Keyword(s):  
Renal Cell Carcinoma ◽  
Peritoneal Dialysis ◽  
Cell Carcinoma ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Renal Cell ◽  
Hemodialysis Patients ◽  
Cystic Disease ◽  
Renal Cystic Disease ◽  
Acquired Renal Cystic Disease ◽  
Acquired Cystic Disease

Purpose To determine whether there is any difference in the prevalence of acquired cystic disease and malignancy of the kidney in patients on continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Data Identification Relevant studies published from January 1983 to June 1991 were identified by manual search and MEDLINE search. Study Selection We reviewed the studies in which acquired renal cystic disease and/or renal cell carcinoma developed in patients on CAPD. Data Extraction Details of the prevalence of acquired cystic disease and renal malignancy as a complication of acquired cysts in CAPD patients were tabulated with the duration of treatment. Results Acquired cystic disease was observed in 195 of 425CAPD patients(41.1%), which is comparable to the prevalence of 47.1% (520/1103) seen in hemodialysis patients. The overall prevalence of renal cell carcinoma accompanying acquired cystic disease in this series of CAPD patients was 2 of 375 (0.4%), which is comparable to the prevalence of 1.5% (17/1103) in hemodialysis patients. So far, eight other instances of renal cell carcinoma complicating acquired cystic disease in CAPD patients were described as case reports. Retroperitoneal bleeding due to the rupture of acquired cysts has been reported on a few occasions. Conclusion In this review no differences were detected in the prevalence or severity of acquired renal cystic disease in patients treated with CAPD as compared with those on hemodialysis. Therefore, the incidence of complications associated with acquired cysts may also be the same for the two treatment modalities, although reports on such complications are rare.

Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancer-specific survival

2011 ◽  
Vol 18 (12) ◽  
pp. 806-812 ◽  
Author(s):  
Toshio Takagi ◽  
Tsunenori Kondo ◽  
Jyunpei Izuka ◽  
Hirohito Kobayashi ◽  
Eri Tomita ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Hemodialysis Patients ◽  
Cancer Specific Survival

628: VHL Mutations of Renal Cell Carcinoma from Hemodialysis Patients

2005 ◽  
Vol 173 (4S) ◽  
pp. 171-171
Author(s):  
Yasunobu Hashimoto ◽  
Fumio Ito ◽  
Shiro Onitsuka ◽  
Hisashi Okuda ◽  
Tsunenori Kondo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Hemodialysis Patients

Successful Response to Nivolumab Plus Ipilimumab Therapy in a Hemodialysis Patient With Metastatic Renal Cell Carcinoma

2021 ◽  
Vol 1 (3) ◽  
pp. 207-211
Author(s):  
HIROSHI MASUDA ◽  
KOSUKE MIKAMI ◽  
KOTARO OTSUKA ◽  
KYOKUSIN HOU ◽  
TAKAHITO SUYAMA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Hemodialysis Patient ◽  
Pulse Therapy ◽  
Hemodialysis Patients ◽  
Combination Immunotherapy ◽  
Efficacy And Safety ◽  
Steroid Pulse

Background/Aim: There are few reports about the administration of nivolumab plus ipilimumab to hemodialysis patients and their efficacy and safety have not been established yet. Case Report: A 74-year-old male, who was receiving hemodialysis, was presented with metastatic renal cell carcinoma (mRCC). Two years later, more metastases were found, hence, immunotherapy involving nivolumab plus ipilimumab was initiated. After two doses of immunotherapy, interstitial pneumonia was observed. Thus, steroid pulse therapy was administered immediately. Subsequently, computed tomography (CT) findings and symptoms improved markedly. One month later, a CT scan showed a nodular shadow and an air cavity. A fungal infection was strongly suspected, so an antifungal drug was administered. Conclusion: Combination immunotherapy with nivolumab plus ipilimumab was demonstrated to be effective in a hemodialysis patient with mRCC.

Sign in / Sign up

Export Citation Format

Share Document